Scarica l'app Stockscreener
6.29
4.31%
0.26
Dopo l'orario di chiusura:
6.28
-0.010
-0.16%
Precedente Chiudi:
$6.03
Aprire:
$6.01
Volume 24 ore:
435.30K
Relative Volume:
1.99
Capitalizzazione di mercato:
$410.91M
Reddito:
-
Utile/perdita netta:
$-44.47M
Rapporto P/E:
-6.1782
EPS:
-1.0181
Flusso di cassa netto:
$-33.50M
1 W Prestazione:
+6.25%
1M Prestazione:
-9.10%
6M Prestazione:
+0.00%
1 anno Prestazione:
+47.31%
Intervallo 1D:
$5.95
$6.46
Intervallo di 1 settimana:
$5.63
$6.46
Portata 52W:
$4.19
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Nome
Eupraxia Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.29 | 406.33M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-16 | Iniziato | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Iniziato | Craig Hallum | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Eupraxia Pharmaceuticals Inc Borsa (EPRX) Ultime notizie
Eupraxia Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesDebt Analysis Report - newsline.com
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders - The Globe and Mail
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K - TipRanks
Eupraxia (EPRX) details 2026 virtual AGM, board nominees and pay plan - Stock Titan
Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders - Stock Titan
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Revision Downgrade - The Legal Advocate
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference - TipRanks
Eupraxia Pharmaceuticals (EPRX) to present at Jefferies Global Healthcare Conference - Stock Titan
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - NorthBayNipissing.com
Biotech Eupraxia heads to New York for Jefferies health conference June 3 - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Rises 2.3% as Stock Approaches Key Resistance LevelDay Trade Opportunities - newsline.com
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Certain Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Common Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating - Investing.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Manchester entities, Besser & Frank disclose EPRX holdings (EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing - TipRanks
Eupraxia Pharmaceuticals: Well-capitalized Into 2H28 >EPRX.T - Moomoo
Eupraxia Pharmaceuticals reports first quarter 2026 financial results - marketscreener.com
Eupraxia Pharmaceuticals Q1 Loss Narrows - Moomoo
Eupraxia (NASDAQ: EPRX) funds EP-104GI trial despite higher quarterly loss - Stock Titan
Eupraxia Pharmaceuticals Says "Well-capitalized into Second Half 2028, Beyond Key Catalysts" With Over US$140M Cash - marketscreener.com
Eupraxia Pharmaceuticals Cites "Robust Response" In Highest Dose Cohort After 36 Weeks Following a Single Treatment of EP-104GI - marketscreener.com
Eupraxia Pharmaceuticals Incurred a Q1 Net Loss of US$12.7M - marketscreener.com
EPRX: Eupraxia Pharmaceuticals Inc.Interactive Chart - Zacks Investment Research
Aisling Capital Management LP's Eupraxia Pharmaceuticals Inc(EPRX) Holding History - GuruFocus
TradingKey - TradingKey
Number of shareholders of Eupraxia Pharmaceuticals, Inc. – FWB:X43 - TradingView
Eupraxia wins new (US) $15.50 target at Leede Financial - Cantech Letter
Eupraxia reports EoE trial data on inflammation and fibrosis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Inc. - Menafn.com
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports EoE trial data on inflammation and fibrosis - Investing.com UK
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - The Manila Times
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Eupraxia Pharmaceuticals Inc Azioni (EPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):